Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy – current evidence and future trends

Bibliography

• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
   PubMed Web of Science ®Google Scholar
• Eiermann WPT, Crown J, Chap L, BCIRG 005 main efficacy analysis: a phase III randomised trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in women with Her-2/neu negative axillary lymph node positive early breast cancer [abstract 77]. San Antonio Breast Cancer Symposium; 2008
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14(3):737-44
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23(19):4265-74
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Untch M, Gelber RD, Jackisch C, Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19(6):1090-6
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Mackey J, Verma S, Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004;5(1):52-8; discussion 9-62
   PubMedGoogle Scholar
• Garcia-Saenz JA, Martin M, Puente J, Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005;6(4):325-9
   PubMedGoogle Scholar
• Stemmler HJ, Kahlert S, Siekiera W, Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 over expressing metastatic breast cancer (MBC). Onkologie 2005;28(11):582-6
   PubMed Web of Science ®Google Scholar
• Tripathy D, Slamon DJ, Cobleigh M, Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22(6):1063-70
   PubMed Web of Science ®Google Scholar
• Montemurro F, Faggiuolo R, Redana S, Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005;23(12):2866-8; discussion 8-9
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Razis E, Tsavdaridis D, Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003;4(2):120-5
   PubMedGoogle Scholar
• Bartsch R, Wenzel C, Hussian D, Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 2006;6:63
   PubMed Web of Science ®Google Scholar
• Orlando L, Cardillo A, Ghisini R, Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;6:225
   PubMed Web of Science ®Google Scholar
• Cancello G, Montagna E, D'Agostino D, Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008;10(4):R60
   PubMedGoogle Scholar
• Metro G, Giannarelli D, Gemma D, Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. Breast J 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Pegram MD, Finn RS, Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17(17):2235-49
   PubMed Web of Science ®Google Scholar
• Shirane MF-OK, Sekiguchi F, Nunomura K, Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Eur J Cancer 2005;Suppl 3:115
   Google Scholar
• von Minckwitz G, du Bois A, Schmidt M, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27(12):1999-2006
   PubMed Web of Science ®Google Scholar
• Jahanzeb M. Continuing trastuzumab beyond progression. J Clin Oncol 2009;27(12):1935-7
   PubMed Web of Science ®Google Scholar
• Gomez HL, Doval DC, Chavez MA, Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26(18):2999-3005
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Storniolo AM, Franco S, A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19(6):1068-74
   PubMed Web of Science ®Google Scholar
• Kaufman B, Trudeau M, Awada A, Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10(6):581-8
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z, Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26(34):5544-52
   PubMed Web of Science ®Google Scholar
• Benz CC, Scott GK, Sarup JC, Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24(2):85-95
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Arboleda J, Reese DM, HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10(12):2435-46
   PubMed Web of Science ®Google Scholar
• Houston SJ, Plunkett TA, Barnes DM, Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79(7-8):1220-6
   PubMed Web of Science ®Google Scholar
• Dowsett M, Allred C, Knox J, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial. J Clin Oncol 2008;26(7):1059-65
   PubMed Web of Science ®Google Scholar
• Xia W, Bacus S, Hegde P, A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006;103(20):7795-800
   PubMed Web of Science ®Google Scholar
• Mackey J, Kaufman B, Clemens M, Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006;100 (Suppl 1):58. S3
   Google Scholar
• Kaufman B, Mackey JR, Clemens MR, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27(33):5529-37
   Google Scholar
• Johnston S, Pippen J Jr, Pivot X, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27(33):5538-46
   Google Scholar
• Xia W, Gerard CM, Liu L, Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005;24(41):6213-21
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66(3):1630-9
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Verma C, Guzman M, Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009;28(6):803-14
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumours over expressing HER2. Clin Cancer Res 2004;10(17):5650-5
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Blackwell KL, Burstein H. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008;26 (20 Suppl): abstract 1015
   PubMedGoogle Scholar
• Jackson JG, St Clair P, Sliwkowski MX, Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signalling and growth effects. Cancer Res 2004;64(7):2601-9
   PubMed Web of Science ®Google Scholar
• Portera CC, Walshe JM, Rosing DR, Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008;14(9):2710-6
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Fumoleau P, Verma S, Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. Meeting Abstracts. J Clin Oncol 2008;26(Suppl 15): abstract 1026
   Web of Science ®Google Scholar
• Zeidler R, Mysliwietz J, Csanady M, The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2008;83(2):261-6
   Google Scholar
• Zeidler R, Reisbach G, Wollenberg B, Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163(3):1246-52
   PubMed Web of Science ®Google Scholar
• Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98(8):2526-34
   PubMed Web of Science ®Google Scholar
• Kiewe P, Hasmuller S, Kahlert S, Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12(10):3085-91
   PubMed Web of Science ®Google Scholar
• Jager M, Ruf P, Schoberth A, Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab. ASCO Abstracts; 2008. p. 3071
   Google Scholar
• Burstein HJ, Sun Y, Tan AR, Dirix L, Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: Phase 2 results in patients with advanced HER2+ breast cancer [abstract 37]. San Antonio Breast Cancer Symposium Abstract book; 2008. p. 31
   Google Scholar
• NIH. Neratinib and Breast cancer. 2009; Available from: http://clinicaltrials.gov/ct2/show/NCT00777101?term=neratinib+and+breast+cancer [Cited 3 March 2009]
   Google Scholar
• Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer (ExteNET). ClinicalTrialsgov identifier: NCT00878709
   Google Scholar
• Modi SBM, Krop IE, Rabbee N, A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2-antibody drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) [poster 168]. ASCO Breast Cancer Symposium 2007; 2007
   Google Scholar
• Beeram MBH, Modi S, Birkner M, A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). J Clin Oncol 2008;26(20 Suppl): abstract 1028
   PubMedGoogle Scholar
• Vukelja SRH, Vogel C, Borson R, A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer [abstract 33]. Cancer Res 2009;69 (Suppl 2):71s
   Web of Science ®Google Scholar
• NIH. An Open-Label Study of Trastuzumab-MCC-DM1 (TDM-1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer. 2009; Available from: http://clinicaltrials.gov/ct2/show/NCT00829166 [Cited 4 March 2009]
   Google Scholar
• NIH. A Study of the Efficacy and Safety of Trastuzumab-Mcc-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease. 2009; Available from: http://clinicaltrials.gov/ct2/show/NCT00679341 [Cited 4 March 2009]
   Google Scholar
• Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15(1):9-14
   PubMed Web of Science ®Google Scholar
• Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13 (Suppl 1):S125-35
   PubMedGoogle Scholar
• Munster PN, Basso A, Solit D, Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: Sausville EA. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001;7:2155-2158. Clin Cancer Res 2001;7(8):2228-36
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Desmedt C, Sotiriou C, HER-2 as a target for breast cancer therapy. Clin Cancer Res 2009;15(6):1848-52
   PubMed Web of Science ®Google Scholar
• Musolino A, Naldi N, Bortesi B, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26(11):1789-96
   PubMed Web of Science ®Google Scholar
• Johnston S, Pegram M, Press M, Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. San Antonio Breast Cancer Symposium General Section 4 2008
   Google Scholar
• Price-Schiavi SA, Jepson S, Li P, Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 2002;99(6):783-91
   PubMed Web of Science ®Google Scholar
• Nagy P, Friedlander E, Tanner M, Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65(2):473-82
   PubMed Web of Science ®Google Scholar
• Carraway KL, Price-Schiavi SA, Komatsu M, Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2001;6(3):323-37
   PubMed Web of Science ®Google Scholar
• Xia W, Liu LH, Ho P, Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23(3):646-53
   PubMed Web of Science ®Google Scholar
• Lu Y, Li X, Liang K, Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007;67(17):8240-7
   PubMed Web of Science ®Google Scholar
• Lee JW, Soung YH, Seo SH, Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12(1):57-61
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Zhao Y, Insulin-like growth factor-I receptor signalling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93(24):1852-7
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65(23):11118-28
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chinratanalab W, Ritter CA, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62(14):4132-41
   PubMed Web of Science ®Google Scholar
• Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 2005;91(2):187-201
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6(2):117-27
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12(4):395-402
   PubMed Web of Science ®Google Scholar
• Le XF, Claret FX, Lammayot A, The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 2003;278(26):23441-50
   PubMed Web of Science ®Google Scholar
• Diermeier S, Horvath G, Knuechel-Clarke R, Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu over expressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005;304(2):604-19
   PubMed Web of Science ®Google Scholar
• Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62(11):3151-8
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Fumoleau P, Verma S, Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 2008;26(15 Suppl): abstract 1026
   Web of Science ®Google Scholar
• Burstein HJ, Sun Y, Tan AR, Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: Phase 2 results in patients with advanced HER2+ breast cancer [abstract 37]. Cancer Res 2009;69 (Suppl 2):73s
   Google Scholar
• Modi S, Sugarman S, Stopeck A, Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2008;26(15 Suppl):1027
   PubMedGoogle Scholar